Further underscoring this, and in sharp contrast to its role in AML, on the background of the APL-typical PML-RARA fusion, the Flt3-ITD mutation reduced the inhibitory effect of atRA on the ability to initiate leukemia in secondary recipients [48]. This evidence concerns the gene PML and acute promyelocytic leukemia.